Bladder Cancer Diagnostics Market by Type of Condition (Transitional cell bladder cancer, Invasive bladder cancer, Superficial bladder cancer, Squamous cell bladder cancer, Other rare types), Type of Test (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Bladder Ultrasound), End user (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography.  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Bladder Cancer Diagnostics Market size was valued at USD 372.1 Mn and expected to grow at 5.2% Compound Annual Growth Rate (CAGR) over 2022 to 2028. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as Transitional Cell Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma..According to the National Institute of Health, approximately 45,000 men and 17,000 women per year are diagnosed with bladder cancer only in U.S. Globally the market for bladder cancer is increasing rapidly and is expected to grow rapidly from 2016 to 2022. According to The American Cancer Society’s estimates for bladder cancer in the United States for 2017 are about 79,030 new cases of bladder cancer (about 60,490 in men and 18,540 in women) were diagnosed and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women) are reporting. Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer diagnostics. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer diagnostics are some of the latest trends that have been observed in the market.

Key Developments: In May 2017. Roche Ltd. received USFDA approval for its VENTENA PD-L1 biomarket test pertaining to bladder cancer diagnosis. In 2016, Pacific Edge Limited launched officially its third bladder cancer diagnostic test Cxbladder Monitor in U.S.

Bladder Cancer Diagnostics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Bladder Cancer Diagnostics Market Dynamics Drivers And Restraints

Increasing incidence rate of bladder cancer cases, technological advancements and innovations with regard to the diagnosis of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer diagnostics globally. In addition, the rise in awareness about bladder diseases, their available options for diagnosis in the market, and increasing health care expenditure are driving the global market for bladder cancer diagnostics. However, the rise in a number of patent expirations, asymptomatic nature of the disease, high cost associated tests, lack of awareness of the technologies factors restraining the revenue growth of the global bladder cancer diagnostics market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Bladder Cancer Diagnostics Market Segmentation

type of condition
  • Transitional cell bladder cancer
  • Invasive bladder cancer
  • Superficial bladder cancer
  • Squamous cell bladder cancer
  • Other rare types
type of test
  • Biopsy
  • Urine Cytology
  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
end user
  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Center
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Afric


Frequently Asked Questions

The bladder cancer diagnostics market is projected to expand at a CAGR of 5.7% during the forecast period  

Abbott Laboratories (U.S), Pfizer (U.S), Sanofi S.A (France), Merck & Co., Inc. (U.S), Novartis (Switzerland)

North America is the fastest-growing region for the bladder cancer diagnostics market

[urltag url='request-table-of-content']

  • Abbott Laboratories (U.S)
  • Pfizer (U.S)
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Sanofi S.A (France)
  • Merck & Co., Inc. (U.S)
  • Novartis (Switzerland)
  • Becton, Dickinson & Co. (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Eli Lilly and Co (U.S)
  • Hoffman-La Roche Ltd. (Switzerland)
  • AstraZeneca plc (UK)
  • GlaxoSmithKline Plc., etc. (UK)
  • Bristol-Myers Squibb (U.S)